Prostate Cancer - Results from #460

Salvage treatments after focal therapy for prostate cancer - a comprehensive review. August 5, 2024

Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review. August 5, 2024

Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP). August 5, 2024

Neurologic Symptoms After 177Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience. August 5, 2024

Incidence and Pitfalls of Adipose Tissue Encountered in Prostatic Transurethral Resections and Related Specimens. August 5, 2024

Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer. August 5, 2024

LX1 Targets Androgen Receptor Variants and AKR1C3 to overcome Therapy Resistance in Advanced Prostate Cancer. August 5, 2024

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. August 5, 2024

Incidence of prostate cancer in Medicaid beneficiaries with and without HIV in 2001-2015 in 14 states. August 2, 2024

The Influence of Disparities on Prostate Cancer at Diagnosis in the Charlotte Metropolitan Area. August 2, 2024

Artificial intelligence-based personalized clinical decision-making for patients with localized prostate cancer: surgery versus radiotherapy. August 2, 2024

Antiandrogen Withdrawal Syndrome After Discontinuation of Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer: A Report of Two Clinical Cases and a Literature Review. August 2, 2024

Treatment patterns for patients with BRCA1/2-positive metastatic castration-resistant prostate cancer. August 2, 2024

Race-Based Screening under the Public Health Ethics Microscope - The Case of Prostate Cancer. August 1, 2024

European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy. August 1, 2024

Early PSA Response by 6 Months is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of TITAN Trial. August 1, 2024

Brachytherapy based microboosting to the dominant intraprostatic lesion in prostate cancer: A systematic review on treatment outcomes and toxicities. August 1, 2024

Cancer centers of excellence for the multidisciplinary management of urologic cancers The intersection between education, research, and healthcare. August 1, 2024

Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer. August 1, 2024

Comparison of data fusion strategies for automated prostate lesion detection using mpMRI correlated with whole mount histology. August 1, 2024

Page 24 of 1435